Latest Articles
-
Will Pfizer Stock See Higher Levels After A 10% Rise In A Month?
The stock price of Pfizer (NYSE: PFE) has seen a rise of 10% over the last month, while it is down 6% YTD. The increase over the previous month can partly be attributed to Pfizer’s acquisition of Arena Pharmaceuticals for $6.7 billion. Th...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) said that the U.S. FDA granted the company’s vaccine candidate targeted at respiratory syncytial virus PF-06928316 (RSVpreF) a Breakthrough Therapy designation. Why? The Breakthrough Therapy designation is meant ...
-
Are Covid-19 Treatment Stocks A Buy As Global Infections Rise Again?
Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus – has declined by about 2% year-to-date, outperforming the S&P 500 which has declined by...
-
What’s Next For Pfizer Stock After A 10% Fall In A Month?
The stock price of Pfizer (NYSE: PFE) has seen a fall of 10% over the last month, while it is up 4% in a week. The decline over the previous month can be attributed to Pfizer’s underwhelming guidance for its Covid-19 vaccine and treatment...
-
Does The Current Dip In Pfizer Stock Offer A Buying Opportunity?
[Updated: Feb 10, 2022] Pfizer Q4 Earnings Update The stock price of Pfizer (NYSE: PFE) has seen a fall of 8% over the last month, while it is down over 3% in a week. The recent decline can be attributed to the company’s mixed Q4 results...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) posted better than expected Q4 2021 earnings, with adjusted EPS coming in at $1.08, up from about $0.43 in Q4 2020. However, revenue growth, which came in at 104% year-over-year, missed estimates. Why? Growth was drive...
-
Forecast Of The Day: Pfizer’s Oncology Revenue
What? Pfizer’s (NYSE:PFE) Oncology Revenue, which includes revenues from Sutent, Xalkori, Inlyta, Ibrance, and other productions, rose from around $9 billion in 2019 to about $11 billion in 2020. We expect the metric to rise to around $12...
-
Will Pfizer Stock See Higher Levels After A Large 18% Rise In A Month?
[Updated: Dec 16, 2021] Pfizer Stock Rise The stock price of Pfizer (NYSE: PFE) has outperformed the broader indices. While the S&P500 index has seen a rise of 1% over the last month or so, PFE stock is up a solid 19%. This also compares wit...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) said that the third dose of its Covid-19 shot was able to neutralize the omicron variant of the novel coronavirus in lab studies. However, a two-dose regimen was much less effective at stopping the concerning new virus v...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) stock rallied to all-time highs of about $54 per share last Friday, although it fell a bit to about $52.50 on Monday. Why? The gains come amid renewed fears of another surge in Covid-19 cases as a highly mutated varian...
-
Will The Rally In Pfizer Stock Continue After A Large 21% Rise In A Month?
[Updated: Nov 18, 2021] Pfizer Stock Update The stock price of Pfizer (NYSE: PFE) has seen a rise of 21% in a month following multiple positive developments, including positive data for its oral Covid-19 treatment pill, upbeat Q3 results, and mo...
-
Will Pfizer Stock Continue To Rise?
[Updated: Nov 8, 2021] PFE Stock Rise The stock price of Pfizer (NYSE: PFE) surged 11% in a single day on Friday Nov 5, 2021. The rise can be attributed to the company announcing positive data for its oral pill for the treatment of Covid-19. Pfi...
-
Company Of The Day: Pfizer
What? The U.S. Centers for Disease Control and Prevention has formally authorized the Pfizer (NYSE:PFE) – BioNTech Covid-19 vaccine for children between the ages of 5 and 11 years old. So What? Pfizer stock remains up by about 24% year-t...
-
Is Pfizer Stock Set To See Higher Levels Post Q3 Results?
Pfizer (NYSE: PFE) is scheduled to report its Q3 2021 results on Tuesday, November 2. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overal...
-
A Year Since Pfizer’s Big Breakthrough, Are Vaccine Stocks Still Worth Investing In?
It’s been almost a year since Pfizer (NYSE:PFE) published incredibly strong efficacy data from its phase 3 Covid-19 vaccine trials, setting the stage for one of the largest inoculation drives in history. Our theme of Covid-19 Vaccine Stoc...
